RT Journal Article
SR Electronic
T1 Evaluation of a Next Generation Sequencing Assay for Hepatitis B Antiviral Drug Resistance on the Oxford Nanopore System
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.01.24314730
DO 10.1101/2024.10.01.24314730
A1 Payne, Michael
A1 Ritchie, Gordon
A1 Lawson, Tanya
A1 Young, Matthew
A1 Jang, Willson
A1 Stefanovic, Aleksandra
A1 Romney, Marc G.
A1 Matic, Nancy
A1 Lowe, Christopher F.
YR 2024
UL http://medrxiv.org/content/early/2024/10/02/2024.10.01.24314730.abstract
AB Background Next-generation sequencing (NGS) for Hepatitis B virus (HBV) antiviral resistance (AVR) testing is a highly sensitive diagnostic method, able to detect low-level mutant subpopulations. Our clinical virology laboratory previously transitioned from DNA hybridization (INNO-LiPA) to NGS, initially with the GS Junior System and subsequently the MiSeq. The Oxford Nanopore Technology (ONT) sequencing system was evaluated for HBV resistance testing, with regards to sequencing accuracy and turn-around time.Methods We performed amplicon sequencing of the HBV polymerase gene from patient plasma and external quality assessment (EQA) samples on the MiSeq Reagent Nano Kit v2 and GridION ONT with R10.4.1 flowcells. Mutational analysis and genotyping were performed by DeepChekAssay-HBV (version 2.0).Results A total of 49 patient samples and 15 EQA samples were tested on both the MiSeq and ONT. There was high agreement for both patient and EQA samples between the MiSeq and ONT systems, with regards to total drug resistance mutations detected and total patient sample agreement, 68/70 (97%) and 47/49 (96%), respectively.Conclusion The ONT NGS platform provided accurate HBV AVR results, with improved turn- around times. Sequencing error rates at AVR codons were below 1%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of British Columbia/Providence Health Care Research Institute Research Ethics Board waived ethics approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.